Table 1.
Literature review of microbial dynamics in patients with oral mucositis using next-generation sequencing methods.
| Author | Study Population (n), Treatment | Sample Collection Site | Time Point (s) | Key Findings |
|---|---|---|---|---|
| Zhu et al., 2017 [34] | NPC (n = 41), CRT |
Retropharyngeal | During RT (10, 20, 30, 40, 50, 60 and 70 Gy) | Developed ≥ grade 2 OM During severe OM: ↑ Actinobacillus, Mannheimia and Streptobacillus During mild OM: ↑ Enhydrobacter, Schwartzia, Pseudoramibacter, Treponema |
| Vesty et al., 2020 [31] | HNC (n = 19), RT | Unstimulated whole saliva Oral mucosa |
Pre-RT and during RT (0–20 Gy, 21–40 Gy and 41–60 Gy) | Developed ≥ grade 2 OM Baseline: ↑ Capnocytophaga, Neisseria, Olsenella, Parviomonas, Tannerella |
| Hou et al., 2018 [30] |
HNC (n = 19), CRT | Oropharyngeal mucosa | Pre-RT and during RT (10, 20, 30, 40, 50, 60, and 70 Gy) | Developed ≥ grade 2 OM OM onset: ↑ Prevotella, Fusobacterium, Treponema, Porphyromonas |
| Reyes-Gibby et al., 2020 [35] | HNC (n = 57), CRT | Buccal mucosa | Pre-RT, OM onset and OM ulceration | Onset of OM non-ulcerated ↑ Prevotella, Fusobacterium, Streptococcus Development of severe OM Baseline: ↑ Cardiobacterium, Granulicatella During OM: ↑ Megasphaera, Cardiobacterium |
| Al-Qadami et al., 2023 [36] | HNC (n = 20), CRT | Stool | Pre-treatment | Developed ≥ grade 3 OM Baseline: ↑ Eubacterium, Victivallis, Ruminococcus Developed grade 0–1 OM Baseline: ↑ Alistipes |
| Hong B-Y et al., 2019 [27] | Solid tumours * (n = 49), 5-FU or doxorubicin QT | Unstimulated saliva Oral mucosa |
Pre-QT, 3 days, 9 days, 14 days after QT infusion | Developed ≥ grade 2 OM During OM: ↑ Fusobacterium, uncultured Clostridiales, Prevotella, Treponema |
| Laheij et al., 2019 [33] | MM (n = 51), auto-HSCT | Oral cavity rinse | Pre auto-HSCT, 0–4 days, 1 w, 4 w and 3 m after SC infusion | Developed ≥ grade 2 OM Baseline: ↑ Veillonella, Enterococcus, Streptococcus, Staphylococcus, Fusobacterium, Prevotella No OM development Baseline: ↑ Streptococcus, Actinomyces |
| Shouval et al., 2020 [37] | Haematological diseases (n = 604), allo-HSCT | Saliva | Pre allo-HSCT and 1w, 2 w, 3 w, 4 w, 5 w after SC infusion | Developed ≥ grade 0–1 Baseline: ↑ Aggregatibacter, TG5, Lactobacillus, Butyrivibrio, Treponema, Schwartzia, Paludibacter Developed ≥ grade 2–3 Baseline: ↑ Kingella, Atopobium, Haemophilus, Fusobacterium, Corynebacterium, Actinomyces, Cardiobacterium Developed ≥ grade 0–1 During OM: ↑ Filifactor, Selenomonas, Brachymonas, Eikenella, Treponema, TG5 Developed ≥ grade 2–3 During OM: ↑ Methylobacterium |
| Bruno et al., 2022 [38] | Haematological diseases (n = 30), allo-HSCT | Buccal mucosa | Pre allo-HSCT, OM ulceration onset and OM healed | Developed ≥ grade 2 OM OM onset: ↑ Mycoplasma and Lactobacillus Post OM: ↑ Staphylococcus, Treponema 2, Enterococcus, Lactobacillus |
| Laheij et al., 2022 [28] | Haematological diseases (n = 50), allo-HSCT | Oral cavity rinse | Pre-SCT and 3 m, 6 m, 12 m and 18 m after SC infusion | Developed ≥ grade 2 OM OM onset: ↑ Mycobacterium, Staphylococcus, Enterococcus |
NPC: Nasopharyngeal Carcinoma; CRT: Chemoradiotherapy; RT: radiotherapy; * Squamous-cell carcinoma, Breast cancer and Adenocarcinoma; MM: Multiple Myeloma; Auto-HSCT: Autologous Haematopoietic Stem Cell Transplantation; SC: Stem Cell; Allo-HSCT: Allogenic Haematopoietic Stem Cell Transplantation; w: week(s); m: month(s); ↑: enrichment or increased abundance.